These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 31775086)

  • 1. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
    Derks JL; van Suylen RJ; Thunnissen E; den Bakker MA; Groen HJ; Smit EF; Damhuis RA; van den Broek EC; Speel EM; Dingemans AC;
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
    Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
    Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
    Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
    Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
    J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
    Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
    Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.
    Yang Q; Xu Z; Chen X; Zheng L; Yu Y; Zhao X; Chen M; Luo B; Wang J; Sun J
    Thorac Cancer; 2019 Apr; 10(4):751-760. PubMed ID: 30734490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
    Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
    J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
    Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
    Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
    Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
    [No Abstract]   [Full Text] [Related]  

  • 19. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.